Navigation Links
Rigel Expects R788 Partnership After Phase 2b Clinical Trials Results
Date:2/3/2009

igel (www.Rigel.com)

Rigel is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory/autoimmune diseases and metabolic diseases. Our pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel's productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market our product candidates. Rigel has product development programs in inflammatory/autoimmune diseases such as rheumatoid arthritis, thrombocytopenia and asthma, as well as in cancer.

This press release contains forward-looking statements, including, but not limited to, statements related to the potential efficacy of R788, enrollment rate in clinical trials of R788, Rigel's plans to pursue clinical development of its product candidates, including R788, the market opportunity for its product candidates, expansion of and changes in its product portfolio, Rigel's plans to pursue collaboration partnerships for product candidates, the estimated charge related to the workforce reduction, the sufficiency of Rigel's cash and cash equivalents to fund current and projected development and operating plans, and Rigel's cash and cash equivalent balance at December 31, 2009. These forward-looking statements are based on the company's current expectations and inherently involve significant risks and uncertainties. Rigel's actual results and the timing of events could differ materially from those anticipated in such forward looking statements as a result of these risks and uncertainties, which include, without limitation, risks related to the development of Rigel's product candidates, including risks related to the timing and success of clinical trials, and potential problems that may arise in the clinical testing and approval process, and
'/>"/>

SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Rigels R788 Phase 2a Results Published in Arthritis and Rheumatism
2. Rigel to Host Conference Call to Discuss Preliminary Phase 2 Study Results of R788 in Lymphoma
3. Rigels R788 Slows Progression of Murine Lupus in Preclinical Studies
4. Rigels R788 Shows Preclinical Activity in Type 1 Diabetes Model
5. Rigel Announces Initiation of Phase 1 Clinical Trial of R348 for Rheumatoid Arthritis, Psoriasis and Other Immune Disorders
6. Rigels R788 Demonstrates Significant Improvement in Rheumatoid Arthritis in Phase 2 Clinical Study
7. Rigel Announces Initiation of Phase 1 Clinical Trial of R343 for Allergic Asthma by its Partner Pfizer
8. CEL-SCI Expects to Take Delivery of New Manufacturing Facility on October 8, 2008
9. Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October
10. The Leukemia & Lymphoma Society and Celator Pharmaceuticals Announce Partnership to Accelerate Development of CPX-351 for AML
11. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Type 2 Diabetes Drug Candidate in Partnership with Ortho-McNeil-Janssen Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... , Jan. 23, 2015 Gem Pharmaceuticals announced today ... been enrolled into the Company,s Phase 2 clinical trial. ... of Gem,s lead compound, GPX-150 (an investigational medication), in ... metastatic disease. Logo - http://photos.prnewswire.com/prnh/20150123/170966LOGO ...
(Date:1/22/2015)...  ViewRay™, a privately held medical device company, announced today ... with ITOCHU Corporation (Tokyo Stock Exchange TYO: 8001) to ... of cancer in Japan . ViewRay,s ... and only MRI-guided radiation therapy system that images and ...
(Date:1/22/2015)... RMD ) today announced results for its quarter ... million, a 10 percent increase compared to the quarter ended ... currency basis). Net income was $91.2 million, an increase of ... Diluted earnings per share for the quarter were $0.64, an ...
Breaking Medicine Technology:Gem Pharmaceuticals Announces Enrollment of Initial Patients in its Phase 2 Clinical Trial to Assess the Efficacy and Safety of GPX-150 in Sarcoma Patients 2ITOCHU Named the Exclusive Distributor for ViewRay's MRI-Guided Radiation Therapy System in Japan 2ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 2ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 3ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 4ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 5ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 6ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 7ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 8ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 9ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 10ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 11
... DIEGO, Sept. 27 Clinicians from three U.S. hospitals ... IV catheter-related bloodstream infections (CRBSI). Data analyzed and presented ... Springs, Ark.; Bethesda North Hospital in Cincinnati; and the ... virtually eliminated such infections, which annually kill some 62,500 ...
... The Colorado Institute for Drug, Device and Diagnostic Development ... solicitation announced in February.  The announcement is made by ... Sophono, Inc., is receiving $600,000 for its Alpha 1 ... is receiving $300,000 for its universal flu vaccine under ...
Cached Medicine Technology:Three U.S. Hospitals Reduce Costly Catheter-Related Bloodstream Infections 2Three U.S. Hospitals Reduce Costly Catheter-Related Bloodstream Infections 3Three U.S. Hospitals Reduce Costly Catheter-Related Bloodstream Infections 4The Colorado Institute for Drug, Device and Diagnostic Development Announces Companies Selected From Its First Solicitation: Sophono, Inc., Receiving $600K; and PeptiVir, Inc., $300K 2
(Date:1/22/2015)... Thousand of GranuFlo lawsuits ( http://www.granuflolawsuit2014.com/ ... GranuFlo and NaturaLyte dialysis concentrates continue to move forward ... Court, District of Massachusetts, Bernstein Liebhard LLP reports. According ... remanded a case filed by the state of Louisiana ...
(Date:1/22/2015)... Joan Lunden, award-winning American journalist, beloved television host, ... 32nd Annual Miami Breast Cancer Conference planned and ... , shares that “a fast-growing, virulent” cancer in her ... not followed up her clean mammogram with an ultrasound. ...
(Date:1/22/2015)... Palm City, Florida (PRWEB) January 22, 2015 ... use cold therapy machine with patented IsoTube design to treat ... has introduced the most progressive and easy to use ... help treat post-operative and sports related orthopedic and muscle injuries. ...
(Date:1/22/2015)... 2015 As interest in the value of ... momentum worldwide, Rev. Eric J. Hall , president and ... (HCCN), will be the keynote speaker on January 27 at ... health system. , The conference, “Hope and Resilience: Innovative and ...
(Date:1/22/2015)... VA (PRWEB) January 22, 2015 Step ... power at the Science Museum of Virginia. Wicked Plants, ... , Wicked Plants unearths 75 poisonous, carnivorous and diabolical ... through each room to uncover the biochemical, physical and ...
Breaking Medicine News(10 mins):Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 5Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 6Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 3Health News:Wicked Plants are taking over the Science Museum of Virginia 2
... , PORTLAND, Ore., July 24 Kim-Chi Vu, M.D., ... FDA-approved microsphere-enhanced collagen filler for the correction of smile lines. Dr. Vu ... its proven success and effectiveness for the long lasting correction of wrinkles. ... is a great product for many reasons. First and foremost it ...
... Thousands respond to the world evangelist,s proclamation of the Good News ... , KIGALI, Rwanda, July 24 ... million people in 100 days, the people of Rwanda continue the ... strong future. Through Kigali Festival with Andrew Palau on July 17-18, ...
... SANTA MONICA, Calif., July 24 The following advisory was issued by Consumer Watchdog: , ... for CIGNA health insurance , , When : , ... : , Hilton , Civil Justice Foundation Breakfast of Champions ... San Francisco, CA 94102 , , What : ...
... LOS ANGELES, July 24 Good vision can be directly ... learning a child does occurs through his eyes and approximately 1 in ... , Does your child have normal, healthy vision needed ... a pediatric ophthalmologist, optometrist or pediatrician? , , ...
... both conditions among Vietnam vets , FRIDAY, July 24 (HealthDay ... were sprayed far and wide by the U.S. military during ... heart disease and Parkinson,s. , An Institute of Medicine ... elevated risk for these two conditions among soldiers who served ...
... , SAN FRANCISCO, July 24 The ... one of over 100 Affiliates nationwide dedicated to putting an end to ... support Bay Area breast health education and breast cancer screening and treatment ... Bay Area Affiliate,s local fundraising efforts, such as the Komen ...
Cached Medicine News:Health News:Dr. Kim-Chi Vu in Portland Selects Artefill to Meet Growing Patient Demand for a Longer Lasting Dermal Filler 2Health News:Dr. Kim-Chi Vu in Portland Selects Artefill to Meet Growing Patient Demand for a Longer Lasting Dermal Filler 3Health News:Rwanda Genocide 100-Day Commemoration Culminates With Kigali Festival With Andrew Palau 2Health News:CIGNA Whistleblower Calls for More Heath Insurance Accountability in Heath Care Reform 2Health News:Back-to-School Health: Are Your Child's Eyes Ready for the Classroom? 2Health News:Back-to-School Health: Are Your Child's Eyes Ready for the Classroom? 3Health News:Agent Orange Linked to Parkinson's, Heart Disease 2Health News:Agent Orange Linked to Parkinson's, Heart Disease 3Health News:Agent Orange Linked to Parkinson's, Heart Disease 4Health News:San Francisco Bay Area Affiliate of the Susan G. Komen for the Cure Funds Over $1.6 Million This Year to Community Outreach Programs 2Health News:San Francisco Bay Area Affiliate of the Susan G. Komen for the Cure Funds Over $1.6 Million This Year to Community Outreach Programs 3Health News:San Francisco Bay Area Affiliate of the Susan G. Komen for the Cure Funds Over $1.6 Million This Year to Community Outreach Programs 4
... and Evisceration. The new MEDPOR ... standard MEDPOR Spheres with a bioactive ... mixed throughout the sphere structure, promotes ... MEDPOR PLUS sphere., ,MEDPOR is a ...
... Cadwell's custom bars have a large ... machined contacts (spaced 3 centimeters center-to-center) ... of repeated cleaning. Polarity indicators are ... snap-on handle fits our bar electrode ...
... Cadwell's custom bars have a ... solid, machined contacts (spaced 3 centimeters ... tear of repeated cleaning. Polarity indicators ... convenient, snap-on handle fits our bar ...
... IOL is the first lens of its kind ... the reduction or elimination of myopia in adults ... and in patients aged 21 and over. ... procedures performed worldwide, results prove that the Verisyse ...
Medicine Products: